These observations may imply that the present treatment protocol, which comprises both csDMARD as mono-therapy and in combination with a bDMARD, does not directly target the mechanisms underlying the increased Gal-9 levels in eRA, despite earlier associations between Gal-9 and TNFα in RA [36]. Here, LGALS9 is linked to rheumatoid arthritis.